Epilepsy surgery in Neurofibromatosis Type 1 - PubMed

Affiliations

• PMID: 23597854
• DOI: 10.1016/j.eplepsyres.2013.02.021

Epilepsy surgery in Neurofibromatosis Type 1

Carmen Barba et al. Epilepsy Res. 2013 Aug.

Abstract

Epilepsy is relatively uncommon in patients with Neurofibromatosis Type 1 (NF1) and seizures are usually well controlled with antiepileptic treatment. However, pharmacoresistance has been reported in patients with NF1 and MRI evidence of malformations of cortical development or glioneuronal tumours. Available information on epilepsy surgery in NF1 is limited to a few patients with gliomas and glioneuronal tumours who underwent lesionectomies. We conducted a survey amongst 25 European epilepsy surgery centres to collect patients with NF1 who had undergone surgery for drug-resistant seizures and identified 12 patients from eight centres. MRI abnormalities were present in all patients but one. They were unilateral temporal in eight, bilateral temporal in one and multilobar or hemispheric in two. Seizures originated from the temporal lobe in ten patients, from the temporo-parieto-occipital region in one, and were bitemporal in one. One year after surgery eight patients were seizure free, one had worthwhile improvement and the remaining three had experienced no benefit. Postoperative outcome, available at 2 years in ten patients and at 5 years in three, remained stable in all but one whose seizures reappeared. Histology revealed dysembryoplastic neuroepithelial tumour (DNET) in five patients, hippocampal sclerosis in four, mixed pathology in one and polymicrogyria in one. No histological abnormality was observed in the remaining patient. Epilepsy surgery can be performed effectively in patients with NF1 provided a single and well-delimited epileptogenic zone is recognized. The high prevalence of DNETs in this series might suggest a non-fortuitous association with NF1.

Keywords: DNET; Epilepsy surgery; Neurofibromatosis Type 1; Temporal lobe.

Similar articles

• Epilepsy in individuals with neurofibromatosis type 1.

  Ostendorf AP, Gutmann DH, Weisenberg JL. Ostendorf AP, et al. Epilepsia. 2013 Oct;54(10):1810-4. doi: 10.1111/epi.12348. Epub 2013 Aug 29. Epilepsia. 2013. PMID: 24032542

• Epilepsy surgery in Belgium, the Flemish experience.

  Boon P, Vandekerckhove T, Calliauw L, Achten E, De Reuck J, Thiery E, Caemaert J, Desomer A, Drieghe C, Vanbelleghem H, Vonck K, Defreyne L, Van Duyse A. Boon P, et al. Acta Neurol Belg. 1996 Mar;96(1):6-18. Acta Neurol Belg. 1996. PMID: 8669230

• Bilateral perisylvian ulegyria: an under-recognized, surgically remediable epileptic syndrome.

  Schilling LP, Kieling RR, Pascoal TA, Kim HI, Lee MC, Kim YH, Paglioli E, Neto PR, Costa JC, Palmini A. Schilling LP, et al. Epilepsia. 2013 Aug;54(8):1360-7. doi: 10.1111/epi.12160. Epub 2013 Apr 15. Epilepsia. 2013. PMID: 23586600

• Hippocampal sclerosis and associated focal cortical dysplasia-related epilepsy in neurofibromatosis type I.

  Gales J, Prayson RA. Gales J, et al. J Clin Neurosci. 2017 Mar;37:15-19. doi: 10.1016/j.jocn.2016.10.048. Epub 2016 Dec 9. J Clin Neurosci. 2017. PMID: 27939253 Review.

• Pharmacoresistant seizures in neurofibromatosis type 1 related to hippocampal sclerosis: Three case presentation and review.

  Algın Dİ, Tezer FI, Oguz KK, Bilginer B, Soylemezoglu F, Saygi S. Algın Dİ, et al. J Clin Neurosci. 2019 Jun;64:14-17. doi: 10.1016/j.jocn.2019.03.055. Epub 2019 Apr 5. J Clin Neurosci. 2019. PMID: 30962059 Review.

Cited by

• Genotype-phenotype correlations in focal malformations of cortical development: a pathway to integrated pathological diagnosis in epilepsy surgery.

  Benova B, Jacques TS. Benova B, et al. Brain Pathol. 2019 Jul;29(4):473-484. doi: 10.1111/bpa.12686. Epub 2019 Jan 27. Brain Pathol. 2019. PMID: 30485578 Free PMC article.

• Epilepsy Mechanisms in Neurocutaneous Disorders: Tuberous Sclerosis Complex, Neurofibromatosis Type 1, and Sturge-Weber Syndrome.

  Stafstrom CE, Staedtke V, Comi AM. Stafstrom CE, et al. Front Neurol. 2017 Mar 17;8:87. doi: 10.3389/fneur.2017.00087. eCollection 2017. Front Neurol. 2017. PMID: 28367137 Free PMC article. Review.

• Non-Oncological Neuroradiological Manifestations in NF1 and Their Clinical Implications.

  Russo C, Russo C, Cascone D, Mazio F, Santoro C, Covelli EM, Cinalli G. Russo C, et al. Cancers (Basel). 2021 Apr 12;13(8):1831. doi: 10.3390/cancers13081831. Cancers (Basel). 2021. PMID: 33921292 Free PMC article. Review.

• Hippocampal sclerosis and epilepsy surgery in neurofibromatosis type 1: case report of a 3-year-old child explored by SEEG and review of the literature.

  Sculier C, Taussig D, Aeby A, Blustajn J, Bekaert O, Fohlen M. Sculier C, et al. Childs Nerv Syst. 2022 Jun;38(6):1217-1221. doi: 10.1007/s00381-021-05343-0. Epub 2021 Sep 10. Childs Nerv Syst. 2022. PMID: 34508273 Review.

• Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.

  Evans DG, Bowers N, Burkitt-Wright E, Miles E, Garg S, Scott-Kitching V, Penman-Splitt M, Dobbie A, Howard E, Ealing J, Vassalo G, Wallace AJ, Newman W; Northern UK NF1 Research Network; Huson SM. Evans DG, et al. EBioMedicine. 2016 May;7:212-20. doi: 10.1016/j.ebiom.2016.04.005. Epub 2016 Apr 13. EBioMedicine. 2016. PMID: 27322474 Free PMC article.

MeSH terms

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal